388 related articles for article (PubMed ID: 27943546)
1. Effect of race and ethnicity on vildagliptin efficacy: A pooled analysis of phase II and III studies.
Kozlovski P; Fonseca M; Mohan V; Lukashevich V; Odawara M; Paldánius PM; Kothny W
Diabetes Obes Metab; 2017 Mar; 19(3):429-435. PubMed ID: 27943546
[TBL] [Abstract][Full Text] [Related]
2. Does the treatment of type 2 diabetes mellitus with the DPP-4 inhibitor vildagliptin reduce HbA1c to a greater extent in Japanese patients than in Caucasian patients?
Foley JE; Bhosekar V; Kawamori R
Vasc Health Risk Manag; 2016; 12():9-12. PubMed ID: 26855580
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
Lukashevich V; Del Prato S; Araga M; Kothny W
Diabetes Obes Metab; 2014 May; 16(5):403-9. PubMed ID: 24199686
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION).
Ji LN; Pan CY; Lu JM; Li H; Zhu DL; Li Q; Li QF; Peng YD; Tian HM; Yao C; Zhao ZG; Wang L; Wang BH;
Diabetes Obes Metab; 2016 Aug; 18(8):775-82. PubMed ID: 27406394
[TBL] [Abstract][Full Text] [Related]
5. Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea.
Xiaoyan C; Jing W; Xiaochun H; Yuyu T; Shunyou D; Yingyu F
Curr Med Res Opin; 2016 Jun; 32(6):1131-6. PubMed ID: 26950829
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.
Pan C; Xing X; Han P; Zheng S; Ma J; Liu J; Lv X; Lu J; Bader G;
Diabetes Obes Metab; 2012 Aug; 14(8):737-44. PubMed ID: 22369287
[TBL] [Abstract][Full Text] [Related]
7. Vildagliptin: clinical trials programme in monotherapy and combination therapy for type 2 diabetes.
Rosenstock J; Fitchet M
Int J Clin Pract Suppl; 2008 Mar; (159):15-23. PubMed ID: 18269437
[TBL] [Abstract][Full Text] [Related]
8. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea.
Garber AJ; Foley JE; Banerji MA; Ebeling P; Gudbjörnsdottir S; Camisasca RP; Couturier A; Baron MA
Diabetes Obes Metab; 2008 Nov; 10(11):1047-56. PubMed ID: 18284434
[TBL] [Abstract][Full Text] [Related]
9. Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus.
Yang W; Xing X; Lv X; Li Y; Ma J; Yuan G; Sun F; Wang W; Woloschak M; Lukashevich V; Kozlovski P; Kothny W;
J Diabetes; 2015 Mar; 7(2):174-81. PubMed ID: 24823599
[TBL] [Abstract][Full Text] [Related]
10. Vildagliptin as add-on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus.
Ning G; Wang W; Li L; Ma J; Lv X; Yang M; Wang W; Woloschak M; Lukashevich V; Kothny W
J Diabetes; 2016 May; 8(3):345-53. PubMed ID: 25929739
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials.
Signorovitch JE; Wu EQ; Swallow E; Kantor E; Fan L; Gruenberger JB
Clin Drug Investig; 2011; 31(9):665-74. PubMed ID: 21819162
[TBL] [Abstract][Full Text] [Related]
12. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial.
Schweizer A; Dejager S; Bosi E
Diabetes Obes Metab; 2009 Aug; 11(8):804-12. PubMed ID: 19476473
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of vildagliptin on glucose fluctuation in Japanese type 2 diabetic patients with ongoing sulfonylurea based oral glycemic agent therapy.
Yoshioka K; Isotani H; Ohashi S; Imamura M
Diabetes Metab Syndr; 2013; 7(1):32-4. PubMed ID: 23517793
[TBL] [Abstract][Full Text] [Related]
14. Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes.
Farngren J; Persson M; Schweizer A; Foley JE; Ahrén B
Diabetes Obes Metab; 2014 Sep; 16(9):812-8. PubMed ID: 24612221
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of vildagliptin as add-on to metformin monotherapy among uncontrolled type 2 diabetes mellitus patients in a real-world setting.
Melzer Cohen C; Davis C; Shalev V; Chodick G
J Diabetes; 2018 Jan; 10(1):68-72. PubMed ID: 28418203
[TBL] [Abstract][Full Text] [Related]
16. Differences in glycemic control across world regions: a post-hoc analysis in patients with type 2 diabetes mellitus on dual antidiabetes drug therapy.
Brath H; Paldánius PM; Bader G; Kolaczynski WM; Nilsson PM
Nutr Diabetes; 2016 Jul; 6(7):e217. PubMed ID: 27376699
[TBL] [Abstract][Full Text] [Related]
17. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.
Filozof C; Gautier JF
Diabet Med; 2010 Mar; 27(3):318-26. PubMed ID: 20536495
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus.
Kikuchi M; Haneda M; Koya D; Tobe K; Onishi Y; Couturier A; Mimori N; Inaba Y; Goodman M
Diabetes Res Clin Pract; 2010 Sep; 89(3):216-23. PubMed ID: 20537746
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment.
Lukashevich V; Schweizer A; Foley JE; Dickinson S; Groop PH; Kothny W
Vasc Health Risk Manag; 2013; 9():21-8. PubMed ID: 23378769
[TBL] [Abstract][Full Text] [Related]
20. Vildagliptin: a review of its use in type 2 diabetes mellitus.
Keating GM
Drugs; 2010 Nov; 70(16):2089-112. PubMed ID: 20964454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
